Insider · CIK 0001644467

Carruthers R Michael

Reports to the SEC for 5 companies · BOULDER, CO

sec.gov

Transactions

Companies

Filings

CIK

0001644467

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-07	OKUROnKure Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+22.4K sh	—	—	22,350
2026-06-04	OKUROnKure Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+7,650 sh	—	—	7,650
2025-08-12	EWTXEdgewise Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,781 sh	—	—	87,590
2025-08-12	EWTXEdgewise Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+26.9K sh	—	—	26,875
2025-08-12	EWTXEdgewise Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+161K sh	—	—	161,250
2025-08-12	EWTXEdgewise Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,781 sh	—	—	17,344
2025-08-12	EWTXEdgewise Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,428 sh	$13.39	−$19.1K	86,162
2025-07-23	Elevation Oncology, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−35K sh	—	—	0
2025-07-23	Elevation Oncology, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−35K sh	—	—	0
2025-07-23	Elevation Oncology, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−31.2K sh	—	—	0
2025-07-23	Elevation Oncology, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15.6K sh	—	—	0
2025-07-23	Elevation Oncology, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−47.3K sh	—	—	0
2025-06-05	Elevation Oncology, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+35K sh	—	—	35,000
2025-05-28	OKUROnKure Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+7,650 sh	—	—	7,650
2025-05-02	EWTXEdgewise Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,314 sh	$16.45	−$21.6K	81,014
2025-05-01	EWTXEdgewise Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,209 sh	—	—	0
2025-05-01	EWTXEdgewise Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,209 sh	—	—	82,328
2024-10-11	EWTXEdgewise Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−70K sh	—	—	127,122
2024-10-11	EWTXEdgewise Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+70K sh	$0.71	+$49.7K	76,904
2024-10-04	OKUROnKure Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+1,324 sh	—	—	1,324
2024-10-04	OKUROnKure Therapeutics, Inc.A Award	Director	AAward	+874 sh	—	—	874
2024-10-04	OKUROnKure Therapeutics, Inc.A Award	Director	AAward	+4,065 sh	—	—	4,939
2024-10-04	OKUROnKure Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+1,760 sh	—	—	1,760
2024-10-04	OKUROnKure Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+15.3K sh	—	—	15,300
2024-09-20	EWTXEdgewise Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+50K sh	$1.93	+$96.5K	56,904
2024-09-20	EWTXEdgewise Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+46.1K sh	$1.93	+$88.9K	81,996
2024-09-20	EWTXEdgewise Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−46.1K sh	$28.59	−$1.32M	35,928
2024-09-20	EWTXEdgewise Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−4,064 sh	$28.59	−$116K	31,864
2024-09-20	EWTXEdgewise Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−25K sh	$28.59	−$714K	6,904
2024-09-20	EWTXEdgewise Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−50K sh	$28.55	−$1.43M	6,904
2024-09-20	EWTXEdgewise Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−96.1K sh	—	—	40,990
2024-08-12	EWTXEdgewise Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+139K sh	—	—	138,750
2024-08-12	EWTXEdgewise Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+23.1K sh	—	—	23,125
2024-06-13	Elevation Oncology, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+35K sh	—	—	35,000
2024-05-02	EWTXEdgewise Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,157 sh	$18.91	−$40.8K	35,230
2024-05-01	EWTXEdgewise Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,208 sh	—	—	37,387
2024-05-01	EWTXEdgewise Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,208 sh	—	—	5,209
2024-01-23	EWTXEdgewise Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−90K sh	$15.78	−$1.42M	29,024
2024-01-23	EWTXEdgewise Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+90K sh	$1.93	+$174K	119,024
2024-01-23	EWTXEdgewise Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−90K sh	—	—	137,058
2023-08-17	EWTXEdgewise Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+200K sh	—	—	200,000
2023-06-22	EWTXEdgewise Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+10K sh	$0.71	+$7,100	29,024
2023-06-22	EWTXEdgewise Therapeutics, Inc. · Stock Options (Right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−10K sh	—	—	197,122
2023-06-16	Elevation Oncology, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+31.2K sh	—	—	31,238
2023-05-02	EWTXEdgewise Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,336 sh	$8.90	−$11.9K	16,126
2023-05-01	EWTXEdgewise Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,208 sh	—	—	17,462
2023-05-01	EWTXEdgewise Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,208 sh	—	—	10,417
2022-08-08	EWTXEdgewise Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+200K sh	—	—	200,000
2022-06-17	Elevation Oncology, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+15.6K sh	—	—	15,619
2022-05-23	EWTXEdgewise Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+9,000 sh	$0.71	+$6,390	12,000

Recent filings

Accepted (ET)
Aug 114
Carruthers R Michael0001644467-26-000002
SEC(opens sec.gov)
Jun 84
Carruthers R Michael0001644467-26-000001
SEC(opens sec.gov)
Aug 144
Carruthers R Michael0001562180-25-005797
SEC(opens sec.gov)
Jul 244
Carruthers R Michael0001415889-25-020236
SEC(opens sec.gov)
Jun 94
Carruthers R Michael0001415889-25-016213
SEC(opens sec.gov)
May 304
Carruthers R Michael0001415889-25-015014
SEC(opens sec.gov)
May 74
Carruthers R Michael0001562180-25-003655
SEC(opens sec.gov)
Oct 164
Carruthers R Michael0001562180-24-007353
SEC(opens sec.gov)
Oct 84
Carruthers R Michael0001415889-24-024912
SEC(opens sec.gov)

Companies

Address

C/O ONKURE THEREAPEUTICS, INC. 6707 WINCHESTER CIRCLE, SUITE 400

BOULDER, CO, 80301